References
- Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480–91.
- Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: An international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17:643–50.
- Hillilä MT, Färkkilä MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther 2004;20:339–45.
- El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: A systematic review. Aliment Pharmacol Ther 2002;16:1171–85.
- Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 2006;24:21–37.
- Simren M, Mansson A, Langkilde AM, Svedlund J, Abrahamsson H, Bengtsson U, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001;63:108–15.
- Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010;25:1366–73.
- Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2009;7:68–72; quiz 3.
- King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352:1187–9.
- Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 2000;14:1001–8.
- Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001;48:14–19.
- Seo AY, Kim N, Oh DH. Abdominal bloating: Pathophysiology and treatment. J Neurogastroenterol Motil 2013;19:433–53.
- Ganiats TG, Norcross WA, Halverson AL, Burford PA, Palinkas LA. Does beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. J Fam Pract 1994;39:441–5.
- Lettieri JT, Dain B. Effects of beano on the tolerability and pharmacodynamics of acarbose. Clin Ther 1998;20:497–504.
- Di Stefano M, Miceli E, Gotti S, Missanelli A, Mazzocchi S, Corazza GR. The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. Dig Dis Sci 2007;52:78–83.
- Drossman D, Corazziari E, Delvaux M, Spiller R, Talley NJ, Thompson WG, et al. Editors Rome III: The functional gastrointestinal disorders. Third Edition. McLean, Virginia: Degnon Associates, Inc; 2006.
- Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395–402.
- Patrick DL, Drossman DA, Frederick I. A quality-of-life measure for persons with irritable bowel syndrome (IBS-QOL): User’s manual. Seattle, Washington: University of Washington; 1997.
- Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47:2615–20.
- Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101:326–33.
- Barba E, Burri E, Accarino A, Cisternas D, Quiroga S, Monclus E, et al. Abdominothoracic mechanisms of functional abdominal distension and correction by biofeedback. Gastroenterology 2015;148:732–9.